Skip to main content
  • Home
  •  Making Gains in HFpEF: An Appraisal of Where We Are Now

Making Gains in HFpEF: An Appraisal of Where We Are Now

Topic:
  • Heart Failure

Available Credit:

  • Not accredited

Course Published On:

Course Expiry Date:

Making Gains in HFpEF: An Appraisal of Where We Are Now
No ratings

Overview

In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with a left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.

 

This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.

Support Statement

This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. The scientific programme has not been influenced in any way by the sponsors.

 

It is not intended for US or UK based healthcare professionals.

Target Audience

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

Upon participation in this programme physicians will be able to:

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF

Module

Title

Duration

Speakers

Presentation & Discussion Patient Case: Typical Patient with HFpEF 15 mins Shelley Zieroth (Manitoba, CA)
Presentation & Discussion SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell 15 mins Javed Butler (Texas, US)
Presentation & Discussion Early Initiation of Foundational Therapy in HF: Why The Urgency? 15 mins Carolyn Lam (Singapore, SG)
Presentation & Discussion.

Patient Case: Typical Patient with HFpEF

Duration: 15 mins

Speakers: Shelley Zieroth (Manitoba, CA)

Presentation & Discussion.

SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell

Duration: 15 mins

Speakers: Javed Butler (Texas, US)

Presentation & Discussion.

Early Initiation of Foundational Therapy in HF: Why The Urgency?

Duration: 15 mins

Speakers: Carolyn Lam (Singapore, SG)

Chair

Shelley Zieroth

St Boniface Hospital, Winnipeg, CA

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada.

View full profile

Panelist

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore

Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore.

View full profile

Javed Butler

University of Mississippi Medical Center, Jackson, MS, US

Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US.

View full profile
This course is not accredited

Related Courses

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
  • 1.00 EBAC

Learning objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
See more
Advancing Patient Care in Hypertrophic Cardiomyopathy
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall recent trial data for novel disease modifying therapy in HCM
  • Describe the evolving guideline directed approach to managing HCM
  • Develop an expert-led approach to implementing novel therapy in clinical practice
See more
A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
  • Not accredited

Learning objectives

  • Recall guideline recommendations for the use of NT-proBNP in heart failure
  • Describe current practices in heart failure diagnosis and the impact on treatment outcomes
  • Develop an optimised approach to the timely diagnosis and management of heart failure
See more
An Expert Approach to Cardio-Renal Protection in CKD
  • 2.00 EBAC

Learning objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
See more
Implementing Heart Failure Guidelines with Collaborative Care
  • Not accredited

Learning objectives

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Incorporating GDMT and PRO Endpoints for Personalised HF Management
  • 1.00 EBAC

Learning objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
See more